Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine

Open Access

Peer-reviewed

Research Article

Yushi Yao,

Affiliation Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China
⨯
Jihao Zhou,

Affiliation Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China
⨯
Lixin Wang,

Affiliation Department of Hematology, Navy General Hospital, Beijing, China
⨯
Xiaoning Gao,

Affiliation Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China
⨯
Qiaoyang Ning,

Affiliation Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China
⨯
Mengmeng Jiang,

Affiliation Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China
⨯
Jia Wang,

Affiliation Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China
⨯
Lili Wang,

Affiliation Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China
⨯
Li Yu

* E-mail: chunhuiliyu@yahoo.com

Affiliation Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China
⨯

Reader Comments (0)

Acute myeloid leukemia
Is the Subject Area "Acute myeloid leukemia" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cytotoxic T cells
Is the Subject Area "Cytotoxic T cells" applicable to this article?

Thanks for your feedback.
T cells
Is the Subject Area "T cells" applicable to this article?

Thanks for your feedback.
Cytotoxicity
Is the Subject Area "Cytotoxicity" applicable to this article?

Thanks for your feedback.
Bone marrow cells
Is the Subject Area "Bone marrow cells" applicable to this article?

Thanks for your feedback.
Leukemia cells
Is the Subject Area "Leukemia cells" applicable to this article?

Thanks for your feedback.
Epigenetic therapy
Is the Subject Area "Epigenetic therapy" applicable to this article?

Thanks for your feedback.